Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function[S]

Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function[S]

L-4F, an apolipoprotein A-I (apoA-I) mimetic peptide (also known as APL180), was administered daily by either intravenous (IV) infusion for 7 days or by subcutaneous (SC) injection for 28 days in patients with coronary heart disease in two distinct clinical studies. L-4F was well tolerated at all do...

Full description

Bibliographic Details
Main Authors: Catherine E. Watson, Nicole Weissbach, Lise Kjems, Surya Ayalasomayajula, Yiming Zhang, Ih Chang, Mohamad Navab, Susan Hama, Greg Hough, Srinivasa T. Reddy, Daniel Soffer, Daniel J. Rader, Alan M. Fogelman, Alison Schecter
Format: Article
Language:English
Published: Elsevier 2011-02-01
Series:Journal of Lipid Research
Subjects:
apolipoprotein
atherosclerosis
high density lipoprotein
C-reactive protein
coronary heart disease
diabetes
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520405322

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520405322

Similar Items